The efficacy and safety of BV plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) in patients with non-sALCL PTCL with low levels of antigen expression (CD30 expression <10% on tumor cells) is being explored in in an ongoing international phase II study (NCT04569032).37 Here, TNFRSF8 is linked to neoplasm.